Can a Pan-RAS inhibitor outsmart pancreatic cancer?

NCT ID NCT07736612

Not yet recruiting Disease control Sponsor: Zhejiang University Source: ClinicalTrials.gov ↗

First seen Jul 30, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This trial is testing whether a new oral drug called HRS-2329, which blocks multiple RAS proteins, can shrink tumors or slow disease when combined with other anti-cancer therapies. It is enrolling adults with advanced pancreatic cancer that has RAS mutations or amplifications and has not responded to prior treatment. The study aims to see if the combination is safe and effective.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: a pan-RAS inhibitor called HRS-2329, taken as a tablet
What this could lead to: If successful, this could point toward a new treatment option for advanced pancreatic cancer, especially for tumors with hard-to-treat RAS mutations.
What could go wrong: This is an early-phase trial, so the drug may not work or could cause unexpected side effects. The combination approach also adds complexity and risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED PANCREATIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC CANCER RAS MUTATIONS OR AMPLIFICATIONS

Contacts and locations

Locations

the First Affiliated Hospital, School of Medicine

Hangzhou, Zhejiang, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.